Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 668Neoplasms 585Colorectal Neoplasms 289Carcinoma, Non-Small-Cell Lung 287Prostatic Neoplasms 277Lung Neoplasms 219Melanoma 159Multiple Myeloma 149Neoplasm Metastasis 147Head and Neck Neoplasms 142Pancreatic Neoplasms 140Ovarian Neoplasms 129Carcinoma, Hepatocellular 127Leukemia, Myeloid, Acute 120Brain Neoplasms 114Squamous Cell Carcinoma of Head and Neck 110Colonic Neoplasms 109Uterine Cervical Neoplasms 107Recurrence 103Stomach Neoplasms 102Lymphoma 100Glioblastoma 91Lymphoma, Non-Hodgkin 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 78Hematologic Neoplasms 78Urinary Bladder Neoplasms 77Lymphoma, Follicular 77Parkinson Disease 4, Autosomal Dominant Lewy Body 74Glioma 73Sarcoma 71

Interventions

cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Hormone Refractory Prostate Cancer × 1 year × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡